Q-omics provides the consensus-scored H2BC19P profile across patient tissues and cancer cell-line models. H2BC19P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H2BC19P is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, H2BC19P RNA expression shows 18,250 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where H2BC19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC19P survival associations across molecular data types. H2BC19P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC19P RNA expression–survival associations across cancer types. High H2BC19P expression shows unfavorable associations in ACC, KIRP, UVM, UCEC, KIRC and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H2BC19P RNA expression.
This table summarizes H2BC19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BC19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC19P shows higher tumor expression in HNSC, KIRC, LUAD, BLCA, LIHC and BRCA. The HNSC box plot shows higher H2BC19P RNA expression in tumor versus normal tissue (log2 FC = +0.476, t-test p < 0.001).
This table shows molecular features associated with H2BC19P in patient tissues and cancer cell lines. In patient samples, H2BC19P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
